Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer

28 Apr 2017

Abstract excerpt

Abstract Triple-negative breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and effective targeted therapies for this disease. Here, we report evidence highlighting the cell-cycle–related kinase CDK7 as a driver and candidate therapeutic target in TNBC. Using publicly available transcriptomic data from a collated set of TNBC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28455421
DOI: 10.1158/0008-5472.can-16-2546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerPMID 28455421Read ↗

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read ↗

CDK7 in breast cancer: mechanisms of action and therapeutic potentialSemantic proximity Read ↗

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Semantic proximity Read ↗

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read ↗

CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancerSemantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulatorsSemantic proximity Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancersSemantic proximity Read ↗

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.